# A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06561685/  
OnCo record `nct06561685` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of FHD-909 run by Eli Lilly and Company, now recruiting.

## Summary

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06561685 by Eli Lilly and Company, with 340 participants planned, started 2024-09-19. Conditions recorded: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer and SMARCA4-Deficient Tumor. Interventions recorded: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel and Nab paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06561685
- Phase: 1
- Setting: An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations
- Sponsor: Eli Lilly and Company
- Enrolled: 340

## Sources

- ClinicalTrials.gov NCT06561685: https://clinicaltrials.gov/study/NCT06561685

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [FHD-909](https://onco.cc/drugs/fhd-909/)
- companies: [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06561685.json